卵巢癌是致死率最高的女性生殖系统肿瘤，其主要转移途径为腹腔转移。然而，目前卵巢癌腹腔转移分子机理尚未阐明。因此，探索卵巢癌腹腔转移关键分子机制对于揭示卵巢癌发生发展机理及探索卵巢癌治疗新策略至关重要。我们前期研究发现，长链非编码RNA分子Lnc-OvM在高转移潜能卵巢癌细胞系中表达显著高于低转移潜能卵巢癌细胞系，且在临床卵巢癌样本中，其表达水平与卵巢癌患者临床分期及预后密切相关。体内外研究发现，沉默Lnc-OvM分子能显著降低卵巢癌的腹腔转移能力。本项目拟在前期工作基础上，采用分子生物学方法从体内外水平系统研究长链非编码RNA分子Lnc-OvM在卵巢癌腹腔转移中的生物学功能，阐明其介导卵巢癌腹腔转移的分子机制，明确长链非编码RNA分子Lnc-OvM作为卵巢癌新型治疗靶标的潜在应用价值，为发展卵巢癌治疗新策略提供理论依据。

Ovarian cancer is one of the most lethal gynecological malignancies, whose primary metastatic site is peritoneal cavity. However, the underlying molecular mechanisms for the peritoneal metastasis of ovarian cancer remain unelucidated. Therefore, it is imperative to identify key molecules responsible for the peritoneal metastasis of ovarian cancer, which is crucial to unravel the molecular pathogenesis of ovarian cancer and to develop new therapeutic options for ovarian cancer patients. We previously identified a novel long non-coding RNA Lnc-OvM, which was over-expressed in ovarian cancer cell lines with higher metastatic potential compared with those with lower metastatic potential. In clinical samples, Lnc-OvM expression was correlated with clinical staging and prognosis of ovarian cancer patients. Moreover, silencing of Lnc-OvM expression could significantly impair ovarian cancer metastasis both in vitro and in vivo. In this project, we aim to explore the molecular mechanisms underlying Lnc-OvM-mediated ovarian cancer metastasis as well as to clarify the potential application values of Lnc-OvM as a novel therapeutic target for ovarian cancer, which might lay theoretical foundations for the development of new treatment strategies for ovarian cancer patients.